{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-24-000005","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.149354+00:00","generated_at":"2026-06-05T13:54:28.055010+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ligand Q4 net income $18.2M ($1.03 diluted); reaffirms 2024 guidance","bullets":["Q4 total revenue $28.1M (down from $50.4M in Q4 2022, which included $23.5M COVID Captisol sales); core adjusted EPS $1.05 vs $0.75.","Full-year 2023 royalties $83.9M (+16% YoY); core adjusted net income $71.7M ($4.06/diluted) vs $41.9M ($2.44).","2024 guidance reaffirmed: total revenue $130-142M, adjusted EPS $4.25-4.75.","FDA approved ZELSUVMI (berdazimer gel) for molluscum contagiosum; Merck's V116 vaccine granted priority review (PDUFA June 17, 2024).","Travere's FILSPARI sNDA for IgAN planned Q1 2024; FSGS data insufficient; Aldeyra received CRL for reproxalap."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-24-000005","json":"https://secwatch.observer/filing/0000886163-24-000005.json","markdown":"https://secwatch.observer/filing/0000886163-24-000005.md","text":"https://secwatch.observer/filing/0000886163-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/0000886163-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/lgnd-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:54:28.055010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22fcd9c58da89074d1b050fd72e443715e14ad9d","claim":"LIGAND PHARMACEUTICALS INC reported financial results for the three and twelve months ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Ligand Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its financial results for the three and twelve months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616324000005/0000886163-24-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}